Cerus Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERS research report →
About the company
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
- CEO
- William Greenman
- IPO
- 1997
- Employees
- 614
- HQ
- Concord, CA, US
Price Chart
- Market Cap
- $633.17M
- P/E
- -61.60
- P/S
- 2.84
- P/B
- 9.08
- EV/EBITDA
- 590.48
- Div Yield
- 0.00%
- Gross Margin
- 54.31%
- Op Margin
- -7.94%
- Net Margin
- -4.29%
- ROE
- -15.36%
- ROIC
- -10.34%
- Revenue
- $206.13M · 14.35%
- Net Income
- $-15,627,000 · 25.29%
- EPS
- $-0.08 · 25.45%
- Op Income
- $-36,346,000
- FCF YoY
- 0.00%
- 52W High
- $3.21
- 52W Low
- $1.15
- 50D MA
- $2.59
- 200D MA
- $2.08
- Beta
- 1.77
- Avg Volume
- 2.57M
Get TickerSpark's AI analysis on CERS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Green Kevin Dennis | other | 63,600 |
| Jun 30, 26 | Green Kevin Dennis | sell | 33,676 |
| Jul 1, 26 | Jayaraman Vivek K | other | 554,529 |
| Jun 30, 26 | Jayaraman Vivek K | other | 80,000 |
| Jun 30, 26 | Jayaraman Vivek K | sell | 42,359 |
| Jul 1, 26 | Jayaraman Vivek K | other | 369,686 |
| Jun 30, 26 | Jensen Chrystal | other | 55,000 |
| Jun 30, 26 | Jensen Chrystal | sell | 24,329 |
| Jun 30, 26 | Greenman William Mariner | other | 192,500 |
| Jun 30, 26 | Greenman William Mariner | sell | 101,919 |
Our CERS coverage
Recent articles, reports, and earnings notes.
No research on CERS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CERS report →Similar companies
Peers in the same neighborhood.